Regeneron's Eylea works better vs Avastin and Lucentis in study
October 17, 2014 at 08:39 AM EDT
Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.